CFO of Alterity Therapeutics (ATHE) details indirect shares and options in Form 3

Rhea-AI Filing Summary

Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.

The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Macnish Niven Abby Sarah

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Listed option exp 26 Feb 2027	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Listed option exp 26 Feb 2027 — 151,510 shares (Indirect, CASAM INVESTMENTS PTY LTD); Ordinary shares — 454,545 shares (Indirect, CASAM INVESTMENTS PTY LTD)

Footnotes (1)

Key Figures

Indirect ordinary shares: 454,545 shares Option underlying shares: 151,510 shares Option exercise price: 0.0280 per share +1 more

4 metrics

Indirect ordinary shares 454,545 shares Indirect holdings via CASAM Investments Pty Ltd

Option underlying shares 151,510 shares Underlying ordinary shares for listed option expiring 26 Feb 2027

Option exercise price 0.0280 per share Exercise price for listed option over ordinary shares

Option expiration date 26 Feb 2027 Expiration date of listed option position

Key Terms

Form 3, Ordinary shares, indirect ownership, listed option

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Ordinary shares financial

""security_title": "Ordinary shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

indirect ownership financial

""ownership_type": "indirect""

listed option financial

""security_title": "Listed option exp 26 Feb 2027""

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Macnish Niven Abby Sarah

(Last) (First) (Middle)

SUITE 4, LEVEL 14

(Street)

MELBOURNE VIC 3000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/09/2026

3. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

3a. Foreign Trading Symbol
[ATH.ASX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	454,545	I	CASAM INVESTMENTS PTY LTD

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Listed option exp 26 Feb 2027	04/10/2026	02/26/2027	Ordinary shares	151,510	$0.028	I	CASAM INVESTMENTS PTY LTD

Explanation of Responses:

	Abby Macnish Niven	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Alterity Therapeutics (ATHE) CFO’s Form 3 filing show?

The Form 3 shows CFO Abby Sarah Macnish Niven’s indirect ownership in Alterity Therapeutics through CASAM Investments Pty Ltd. It discloses 454,545 ordinary shares plus a listed option over 151,510 underlying shares, providing a baseline view of her reported equity stake.

How many Alterity Therapeutics ordinary shares are reported in this Form 3?

The Form 3 reports 454,545 ordinary shares of Alterity Therapeutics held indirectly via CASAM Investments Pty Ltd. This figure represents the reported share position attributed to the CFO’s associated entity at the time of the filing, not a new purchase or sale event.

What options are disclosed for ATHE’s CFO in the Form 3 filing?

The filing lists a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares with an exercise price of 0.0280 per share. This derivative position is held indirectly and adds to the CFO’s potential future equity exposure.

Is the ATHE Form 3 filing reporting new insider buying or selling activity?

No, this Form 3 describes holdings rather than explicit buy or sell transactions. It establishes the CFO’s indirect ownership baseline in Alterity Therapeutics, including both ordinary shares and listed options, without indicating recent open-market trading activity in the reported data.

How are the ATHE CFO’s holdings structured in this Form 3?

All reported positions are held indirectly through CASAM Investments Pty Ltd. The filing shows 454,545 ordinary shares and a listed option over 151,510 underlying shares, clarifying that the equity interests are attributed via this entity rather than direct personal registration.